<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571076</url>
  </required_header>
  <id_info>
    <org_study_id>1112-C-091-CR</org_study_id>
    <nct_id>NCT01571076</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor</brief_title>
  <official_title>Prospective and Randomized Study of the Use of Comparative Genomic Hybridization (CGH) Arrays to Study Embryo Aneuploidies in Female Advanced Age and Male Factor In Vitro Fertilization (IVF) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preimplantation Genetic Screening (PGS) is used for the selection of chromosomally normal
      embryos before the transfer in IVF treatments in many cases. There is great debate in the
      scientific community as to whether this is an efficient practice in patients of different
      prognosis.

      This prospective and randomized study seeks to study the results of chromosomal diagnosis
      using the new Comparative Genomic hybridization (CGH) arrays technique by practicing
      Preimplantation Genetic Screening (PGS) in day three biopsy on one arm of the study and not
      on the other arm in order to compare the results. The investigators will study the ongoing
      pregnancy rate of each oocyte retrieval and the ongoing implantation rate with Day 5 embryos
      (blastocysts) in IVF/ intracytoplasmic sperm injection (ICSI) treatments of embryos from two
      different groups of patients: Advanced Age Female Patients (38 - 41 years of age) and Male
      severe factor (≥2 million spermatozoids/ml.).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Implantation and Pregnancy Rate</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Embryo Aneuploidies</condition>
  <condition>Implantation Rates</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group B - Severe Male Factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Advanced Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Advanced Age</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Severe Male Factor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PGS</intervention_name>
    <description>Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group A - Severe Male Factor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PGS</intervention_name>
    <description>Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group A - Advanced Age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged culture</intervention_name>
    <description>The embryos will be in prolonged culture and on going embryos transferred on Day 5 .</description>
    <arm_group_label>Group B - Advanced Age</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged culture</intervention_name>
    <description>Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.</description>
    <arm_group_label>Group B - Severe Male Factor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:

          -  Women's Age: 38- 41 years old (both included)

          -  Men's Age: 18-60 years old (both included)

          -  Ovulation triggered with human chorionic gonadotrophin (hCG) (Ovitrelle, Merck-Serono,
             Madrid)

          -  Number of Oocytes metaphase II (MII): ≥ 5 (fresh, not vitrified)

          -  Quality of semen: ≥ 5 millions spermatozoids/ml

        Exclusion Criteria: ADVANCED AGE and SEVERE MALE FACTOR:

          -  Number of Oocytes metaphase II (MII): &lt;5 oocytes

          -  Number of Oocytes obtained: &gt;20

          -  Estradiol on the day of human chorionic gonadotrophin (hCG) &gt;3000 pgr/ml
             administration.

          -  Progesterone on the day of hCG &gt;1,5 pmol/l administration

          -  ≥ 2 previous miscarriages:biochemical,clinical,ectopic or a combination)

          -  Any un corrected alteration in a previous study.

          -  Other indications of (Preimplantation Genetic Diagnosis.Screening) PGD-S, such as
             monogenic illnesses, translocations, repeated implantation failure, repeated
             miscarriages, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Simon, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Rubio, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Igenomix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Rubio, PhD</last_name>
    <phone>34963905301</phone>
    <email>carmen.rubio@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Atkinson, MA</last_name>
    <phone>34963050900</phone>
    <email>leslie.atkinson@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SPAIN: IVI Valencia, IVI Barcelona, IVI Madrid</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Rubio, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gema Castillon, MDPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Guillen, MDPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Bellver, MDPhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Carlos Simon</investigator_full_name>
    <investigator_title>Director of Clinical Research IVI Valencia</investigator_title>
  </responsible_party>
  <keyword>PGS</keyword>
  <keyword>CGH</keyword>
  <keyword>Aneuploidy</keyword>
  <keyword>Advanced maternal age</keyword>
  <keyword>Male factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

